• Explore /
  • Poster
  • / Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.

Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.

Abstract Poster

Authors

Jeffrey Jones

Jeffrey Alan Jones

The Ohio State University Comprehensive Cancer Center, Columbus, OH

Jeffrey Alan Jones , William G. Wierda , Michael Y. Choi , Matthew Steven Davids , Bruce D. Cheson , Richard R. Furman , Nicole Lamanna , Paul M. Barr , Herbert Aaron Eradat , Ahmad Sami Halwani , Leonard T. Heffner , Brenda Chyla , Ming Zhu , Jalaja Potluri , Maria E. Verdugo , Rod Humerickhouse , Anthony R. Mato , Steven Coutre

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT02141282

Citation

J Clin Oncol 34, 2016 (suppl; abstr 7519)

DOI

10.1200/JCO.2016.34.15_suppl.7519

Abstract #

7519

Poster Bd #

75

Abstract Disclosures

Similar Posters

First Author: Rajat Bannerji

First Author: Nimer Alsaid

First Author: Stéphane De Botton

Poster

2023 ASCO Annual Meeting

Reduction in Curie score in neuroblastoma patients treated with naxitamab.

Reduction in Curie score in neuroblastoma patients treated with naxitamab.

First Author: Jaume Mora